scholarly journals Study of Glutoxim antiviral activity in the fibroblast cell line infected with vesicular stomatitis virus

2018 ◽  
Vol 2018 (6) ◽  
pp. 25-29 ◽  
Author(s):  
Сергей Ожерелков ◽  
Sergey Ozherelkov ◽  
Татьяна Кожевникова ◽  
Tat'yana Kozhevnikova ◽  
Александр Санин ◽  
...  

New strategy for the treatment of animal infectious diseases is based upon the modulation of the host immune response in order to enhance the clearance of infectious agents and reduce the damaging effects of inflammation in the tissues. The modern approach to the use of immunomodulators (IMD) in veterinary practice consists in the usage of such drugs, which are not only immunomodulating, but also have antiviral, antioxidant, anti-inflammatory, hemostimulating and/or other important properties. The aim of the study was to identify possible antiviral activity of known IMD Glutoxim (GLT) during infection of diploid fibroblast cell lines M-8 and M-22 with vesicular stomatitis virus (VSV). Materials and methods: VSV, strain Indiana, was used. Antiviral activity of GLT investigated: 1) at doses recommended for experiments in vitro: 1, 4 and 8 µg/ml; 2) at low doses: 0,1; 0,25 and 0,5 µg/ml. GLT was added to the cell monolayer according to preventive (for 24 hours prior to VSV infection of cells) and treatment (unanimous with VSV infection) protocols. The antiviral activity of GLT was assessed by the following criteria: ability of the drug to prevent the development of virus cytopathic action, to inhibit the reproduction of VSV, and by expessing virucidal action. Results: GLT in doses recommended for in vitro experiments (1, 4, 8 µg/ml) did not delay the development of a specific virus-induced cytopathic action. The VSV titers in infected cells in the presence of GLT did not differ from those in the control cell lines infected with VSV without the addition of GLT. The latter had no virucidal effect against the VSV. Inoculation of GLT into the cell culture at low doses of 0.1, 0.25 and 0.5 mg/ml led to a significant (more than 100-fold) inhibition of VSV replication 24 hours after infection of cells. At later stages, 40 and 48 hours following infection, the antiviral effect of GLT was not detected. Thus, we established that GLT possesses antiviral effect in vitro, which is manifested 24 hours following infection of diploid fibroblast cell lines with VSV.

Hernia ◽  
2016 ◽  
Vol 21 (3) ◽  
pp. 407-416 ◽  
Author(s):  
R. Wiessner ◽  
T. Kleber ◽  
N. Ekwelle ◽  
K. Ludwig ◽  
D.-U. Richter

Virology ◽  
2008 ◽  
Vol 373 (2) ◽  
pp. 352-361 ◽  
Author(s):  
Z.Q. Yuan ◽  
E.A. Gault ◽  
P. Gobeil ◽  
C. Nixon ◽  
M.S. Campo ◽  
...  

1980 ◽  
Vol 15 (1) ◽  
pp. 53-70 ◽  
Author(s):  
George G. Rose ◽  
Toshihiko Yajima ◽  
Charles J. Mahan

2009 ◽  
Vol 182 (2) ◽  
pp. 327-335 ◽  
Author(s):  
Carina Romanutti ◽  
Andrea C. Bruttomesso ◽  
Viviana Castilla ◽  
Juan A. Bisceglia ◽  
Lydia R. Galagovsky ◽  
...  

1980 ◽  
Vol 15 (3) ◽  
pp. 267-287 ◽  
Author(s):  
Toshihiko Yajima ◽  
George G. Rose ◽  
Charles J. Mahan

2014 ◽  
Vol 58 (7) ◽  
pp. 4042-4047 ◽  
Author(s):  
Amedeo De Nicolò ◽  
Marco Simiele ◽  
Andrea Calcagno ◽  
Adnan Mohamed Abdi ◽  
Stefano Bonora ◽  
...  

ABSTRACTProtease inhibitors are largely used for the treatment of HIV infection in combination with other antiretroviral drugs. Their improved pharmacokinetic profiles can be achieved through the concomitant administration of low doses of ritonavir (RTV), a protease inhibitor currently used as a booster, increasing the exposure of companion drugs. Since ritonavir-boosted regimens are associated with long-term adverse events, cobicistat, a CYP3A4 inhibitor without antiviral activity, has been developed. Recently, high intracellular concentrations of ritonavir in lymphocytes and monocytes were reported even when ritonavir was administered at low doses, so we aimed to compare its theoretical antiviral activity with those of the associated protease inhibitors. Intracellular concentrations of ritonavir and different protease inhibitors were determined through the same method. Inhibitory constants were obtained from the literature. The study enrolled 103 patients receiving different boosted protease inhibitors, darunavir-ritonavir 600 and 100 mg twice daily and 800 and 100 mg once daily (n= 22 and 4, respectively), atazanavir-ritonavir 300 and 100 mg once daily (n= 40), lopinavir-ritonavir 400 and 100 mg twice daily (n= 21), or tipranavir-ritonavir 500 and 200 mg twice daily (n= 16). According to the observed concentrations, we calculated the ratios between the intracellular concentrations of ritonavir and those of the companion protease inhibitor and between the theoretical viral protease reaction speeds with each drug, with and without ritonavir. The median ratios were 4.04 and 0.63 for darunavir-ritonavir twice daily, 2.49 and 0.74 for darunavir-ritonavir once daily, 0.42 and 0.74 for atazanavir-ritonavir, 0.57 and 0.95 for lopinavir-ritonavir, and 0.19 and 0.84 for tipranavir-ritonavir, respectively. Therefore, the antiviral effect of ritonavir was less than that of the concomitant protease inhibitors but, importantly, mostly with darunavir. Thus, furtherin vitroandin vivostudies of the RTV antiviral effect are warranted.


1978 ◽  
Vol 57 (11-12) ◽  
pp. 1003-1015 ◽  
Author(s):  
George G. Rose ◽  
Toshihiko Yajima ◽  
Charles J. Mahan

Using 16 human gingival fibroblast cell lines from patients with periodontitis, Dilantin hyperplasia, and nonpathological gingiva, a microscopic assay was developed to quantitate the cells' ability to lyse collagen substrates. The method employs tissue culture chambers with one cover slip partially coated with a thin layer of undenatured fibrillar bovine codlagen. The assay measures the relative numbers and sizes of holes in the collagen within defined regions of the cover slips effected by the phagocytotic and collagenolytic performance (PCP) of the population of fibroblasts growing on the cover slip for 5 days. The effect on the PCP index by serum, heparin, prostaglandins, and endotoxin was evaluated.


Sign in / Sign up

Export Citation Format

Share Document